drugset / Trial / NCT02293993
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Non-randomizedFactorialOpen-labelTreatment
Summary
To evaluate the tolerability and pharmacokinetics of SGI-110 when administered subcutaneously to Japanese patients with acute myeloid leukemia (AML).
Timeline
- Start
- 2015-01-07
- Primary completion
- 2017-06-14
- Completion
- 2019-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guadecitabine | Oligonucleotide (other) | 36 mg/m2 | Subcutaneous |
| Subject | Guadecitabine | Oligonucleotide (other) | 60 mg/m2 | Subcutaneous |
| Subject | Guadecitabine | Oligonucleotide (other) | 90 mg/m2 | Subcutaneous |